학술논문

Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: Additional response outcomes from RELATIVITY-047
Document Type
Journal
Source
ANNALS OF ONCOLOGY; SEP 2022, 33 7, pS920-pS921, 2p. Supplement: 7
Subject
Language
English
ISSN
15698041